Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis
about
Recent developments and future prospects in the treatment of visceral leishmaniasisMiltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendationsMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisDrug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasisDecline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in IndiaLeishmaniasis: an update of current pharmacotherapy.Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.An update on pharmacotherapy for leishmaniasisPKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, IndiaClinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature ReviewTo evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL).Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniaEfficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis.Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012.Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.Chemotherapeutics of visceral leishmaniasis: present and future developments.Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.Visceral Leishmaniasis - Current Treatments and Needs
P2860
Q26740563-A370C4A2-4C40-418F-9AFD-42C4E9A23AA9Q28088410-40100A79-696D-4085-BB68-D7804E2303B4Q28271849-59B1728F-9DAD-4569-8158-80329FCCB32FQ28483875-7F4192D7-D223-4504-A274-CACA57480913Q28550454-5E445EBD-193E-4CC4-B18F-68ED217FFBDFQ34318765-DDD29072-1EDA-4B94-854B-BE31D209F65EQ34328882-EA6690B4-17B6-4311-A717-DD7EAC25852CQ34945204-797B8AA0-FE68-403C-929C-4AC9B89531DFQ35814962-EF89D105-BE07-460C-90B1-CD169F609018Q35822187-B829D1AB-959C-481C-8DB3-4C29C7276DD7Q36094815-84C65C4E-276C-4436-8086-E59BF13FC31DQ36326798-ECC45878-9448-46CA-BC13-9A609E9EB06EQ36920274-EC047459-678F-4DEA-AE25-D12BC6AE0B8DQ36962106-DB1A5719-8878-4195-A124-DD6C60F15E1BQ37053235-6EC1DCCD-9F23-41B9-BD39-A218F440C16EQ38108301-C6A1D7B7-14B0-4033-A76C-32470833C9EBQ39226324-52D057BD-70FD-4A7A-9CBB-B3264A5FA107Q42537676-93ABD7C9-E5DA-4FE9-97F2-193B5532D4D9Q45998754-08B4679B-CCD2-49BC-B138-2E40D48F59B3Q46713325-93DC0235-0BDA-4A67-958B-8838C1051325Q47106631-29182CE9-D2CA-4AFF-867D-CEBED20AD69FQ55464876-12303FC8-47D2-4834-A894-F98F4949371BQ59003562-D2D6B4D7-DF12-43E8-9671-F0571EED58EB
P2860
Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis
description
im August 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 August 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2011
@uk
name
Miltefosine as an effective ch ...... kala-azar dermal leishmaniasis
@en
Miltefosine as an effective ch ...... kala-azar dermal leishmaniasis
@nl
type
label
Miltefosine as an effective ch ...... kala-azar dermal leishmaniasis
@en
Miltefosine as an effective ch ...... kala-azar dermal leishmaniasis
@nl
prefLabel
Miltefosine as an effective ch ...... kala-azar dermal leishmaniasis
@en
Miltefosine as an effective ch ...... kala-azar dermal leishmaniasis
@nl
P2093
P2860
P1476
Miltefosine as an effective ch ...... kala-azar dermal leishmaniasis
@en
P2093
P2860
P304
P356
10.1111/J.1365-2133.2011.10402.X
P407
P577
2011-08-01T00:00:00Z